The US Food and Drug Administration has granted Amgen (Nasdaq: AMGN) a label extension for Repatha (evolocumab), to include prevention of heart attacks and strokes.
The decision was based on data from the FOURIER study which showed a reduction in the risk of heart attack by 27%, of stroke by 21% and of coronary revascularization by 22%.
Repatha is a new kind cholesterol-lowering biologic, called a PCSK9 inhibitor, whch targets a particular protein generated by liver cells.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze